Publication:
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

Simple item page
dc.contributor.authorForbes, Lisa R
dc.contributor.authorVogel, Tiphanie P
dc.contributor.authorCooper, Megan A
dc.contributor.authorCastro-Wagner, Johana
dc.contributor.authorSchussler, Edith
dc.contributor.authorWeinacht, Katja G
dc.contributor.authorPlant, Ashley S
dc.contributor.authorSu, Helen C
dc.contributor.authorAllenspach, Eric J
dc.contributor.authorSlatter, Mary
dc.contributor.authorAbinun, Mario
dc.contributor.authorLilic, Desa
dc.contributor.authorCunningham-Rundles, Charlotte
dc.contributor.authorEckstein, Olive
dc.contributor.authorOlbrich, Peter
dc.contributor.authorGuillerman, R Paul
dc.contributor.authorPatel, Niraj C
dc.contributor.authorDemirdag, Yesim Y
dc.contributor.authorZerbe, Christa
dc.contributor.authorFreeman, Alexandra F
dc.contributor.authorHolland, Steven M
dc.contributor.authorSzabolcs, Paul
dc.contributor.authorGennery, Andrew
dc.contributor.authorTorgerson, Troy R
dc.contributor.authorMilner, Joshua D
dc.contributor.authorLeiding, Jennifer W
dc.date.accessioned2023-01-25T10:21:19Z
dc.date.available2023-01-25T10:21:19Z
dc.date.issued2018-08-06
dc.description.abstractTreatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.
dc.identifier.doi10.1016/j.jaci.2018.07.020
dc.identifier.essn1097-6825
dc.identifier.pmcPMC6322659
dc.identifier.pmid30092289
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322659/pdf
dc.identifier.unpaywallURLhttp://www.jacionline.org/article/S0091674918311278/pdf
dc.identifier.urihttp://hdl.handle.net/10668/12815
dc.issue.number5
dc.journal.titleThe Journal of allergy and clinical immunology
dc.journal.titleabbreviationJ Allergy Clin Immunol
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1665-1669
dc.pubmedtypeLetter
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, N.I.H., Intramural
dc.rights.accessRightsopen access
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshChild
dc.subject.meshFemale
dc.subject.meshGain of Function Mutation
dc.subject.meshHumans
dc.subject.meshImmunologic Deficiency Syndromes
dc.subject.meshJanus Kinases
dc.subject.meshMale
dc.subject.meshNitriles
dc.subject.meshPiperidines
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyrazoles
dc.subject.meshPyrimidines
dc.subject.meshPyrroles
dc.subject.meshSTAT1 Transcription Factor
dc.subject.meshSTAT3 Transcription Factor
dc.subject.meshTreatment Outcome
dc.titleJakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number142
dspace.entity.typePublication

Files

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía